Regeneron, Sanofi deepen antibody collaboration with expanded alliance

Genmab and AbbVie's Epkinly showed promising results in a Phase 3 study, reducing disease progression or death risk by 51% in lymphoma patients. IntraBio was acquired by Shionogi for $2 billion, expanding Aqneursa's approvals. Novartis invested up to $7.8 billion in Abogen Biosciences. Eli Lilly and CSL also announced significant biopharma deals. Sarepta Therapeutics presented positive Elevidys data, with upcoming catalysts for its treatments.

Regeneron Pharmaceuticals (REGN) received an 'Overweight' rating from JP Morgan, with a price target raised from $900 to $950. The company's GF Value™ suggests a 19.3% undervaluation, and its GF Score™ is 87/100, indicating strong financial performance. Analysts cite confidence in Regeneron's growth trajectory and market position, particularly due to its flagship drugs Eylea and Dupixent.

Regeneron (REGN) announced a $22M Q3 R&D charge, reducing EPS by $0.18. The company expanded its partnership with Sanofi (SNY) in an $8B deal, including a $1B upfront payment for immunology therapies. REGN's GF Value™ suggests it is modestly undervalued with a 19.7% margin of safety. The GF Score™ is 87/100, indicating strong fundamentals. Insider activity shows $12.9M in selling over the past year, while 10 premium gurus hold REGN shares, with 8 adding and 4 trimming positions.

Regeneron and Sanofi expanded their antibody collaboration, targeting four new antibodies. Sanofi will pay $1.0 billion upfront, with up to $7.0 billion in milestones. They will share profits and costs, with Regeneron leading U.S. efforts and Sanofi leading global commercialization. The agreement aims to expand their IL-4/IL-13 immunology pipeline.

REGENERON PHARMACEUTICALS, INC. (REGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 1.01. Entry into a Material Definitive Agreement. On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“ Sanofi Biotechnol

Regeneron (NASDAQ: REGN) presented new clinical data at ESMO 2026, including long-term survival outcomes for Libtayo in high-risk CSCC and neoadjuvant treatment data. The company also shared updates on Factor XI antibodies for cancer-associated thrombosis. Regeneron's pipeline includes over 30 cancer types, with Libtayo as a key therapy.